Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Oct, 2016 | Pages:
107 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Pipeline Review, H2 2016', provides in depth analysis on Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) targeted pipeline therapeutics. The report provides comprehensive information on the Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note: *Certain sections in the report may be removed or altered based on the availability and relevance of data. *Updated report will be delivered in 48 hours of order confirmation. Scope - The report provides a snapshot of the global therapeutic landscape for Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - The report reviews Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) targeted therapeutics and enlists all their major and minor projects - The report assesses Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) Overview 9 Therapeutics Development 10 Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Products under Development by Stage of Development 10 Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Products under Development by Therapy Area 11 Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Products under Development by Indication 12 Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Pipeline Products Glance 14 Late Stage Products 14 Early Stage Products 15 Unknown Stage Products 16 Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Products under Development by Companies 17 Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Products under Development by Universities/Institutes 21 Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Therapeutics Assessment 23 Assessment by Monotherapy/Combination Products 23 Assessment by Mechanism of Action 24 Assessment by Route of Administration 26 Assessment by Molecule Type 28 Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Companies Involved in Therapeutics Development 30 Adamis Pharmaceuticals Corporation 30 Argos Therapeutics, Inc. 31 Asterias Biotherapeutics, Inc. 32 e-Therapeutics Plc 33 F. Hoffmann-La Roche Ltd. 34 Inovio Pharmaceuticals, Inc. 35 Invectys SA 36 Johnson & Johnson 37 Komipharm International Co., Ltd. 38 Mediolanum farmaceutici S.p.A. 39 Ultimovacs AS 40 Vaxon Biotech 41 Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Drug Profiles 42 AGS-499 - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 ASTVAC-1 - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 ASTVAC-2 - Drug Profile 45 Product Description 45 Mechanism Of Action 45 R&D Progress 45 ETS-2300 - Drug Profile 47 Product Description 47 Mechanism Of Action 47 R&D Progress 47 Gene Therapy to Activate Telomerase for Alzheimer's Disease - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 Gene Therapy to Activate Telomerase for Alzheimer's Disease and Atherosclerosis - Drug Profile 49 Product Description 49 Mechanism Of Action 49 R&D Progress 49 Gene Therapy to Activate Telomerase for Aplastic Anemia - Drug Profile 50 Product Description 50 Mechanism Of Action 50 R&D Progress 50 GX-301 - Drug Profile 51 Product Description 51 Mechanism Of Action 51 R&D Progress 51 imetelstat sodium - Drug Profile 52 Product Description 52 Mechanism Of Action 52 R&D Progress 52 INO-1400 - Drug Profile 59 Product Description 59 Mechanism Of Action 59 R&D Progress 59 INO-5400 - Drug Profile 60 Product Description 60 Mechanism Of Action 60 R&D Progress 60 INVAC-1 - Drug Profile 61 Product Description 61 Mechanism Of Action 61 R&D Progress 61 KML-001 - Drug Profile 62 Product Description 62 Mechanism Of Action 62 R&D Progress 62 rocapuldencel-T - Drug Profile 64 Product Description 64 Mechanism Of Action 64 R&D Progress 64 Small Molecule to Target Telomerase for Lung Cancer - Drug Profile 71 Product Description 71 Mechanism Of Action 71 R&D Progress 71 Telin - Drug Profile 72 Product Description 72 Mechanism Of Action 72 R&D Progress 72 TeloB-VAX - Drug Profile 73 Product Description 73 Mechanism Of Action 73 R&D Progress 73 tertomotide - Drug Profile 74 Product Description 74 Mechanism Of Action 74 R&D Progress 74 UCPVax - Drug Profile 76 Product Description 76 Mechanism Of Action 76 R&D Progress 76 UV-1 - Drug Profile 77 Product Description 77 Mechanism Of Action 77 R&D Progress 77 Vaccine to Target Telomerase for Oncology - Drug Profile 78 Product Description 78 Mechanism Of Action 78 R&D Progress 78 Vaccine to Target Telomerase Reverse Transcriptase for Solid Tumor - Drug Profile 79 Product Description 79 Mechanism Of Action 79 R&D Progress 79 Vbx-016 - Drug Profile 80 Product Description 80 Mechanism Of Action 80 R&D Progress 80 Vbx-026 - Drug Profile 81 Product Description 81 Mechanism Of Action 81 R&D Progress 81 Vx-001 - Drug Profile 82 Product Description 82 Mechanism Of Action 82 R&D Progress 82 Vx-006 - Drug Profile 84 Product Description 84 Mechanism Of Action 84 R&D Progress 84 Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Dormant Projects 85 Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Discontinued Products 89 Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Featured News & Press Releases 92 Sep 12, 2016: Geron Provides Update on Imetelstat Trials Being Conducted by Janssen 92 Jul 13, 2016: Geron Announces Issuance of U.S. Patents Related to Imetelstat 93 Jun 13, 2016: Independent Data Monitoring Committee Recommends Continuation of ADAPT Phase 3 Clinical Trial of AGS-003 in Metastatic Renal Cell Carcinoma Following Interim Data Review 94 May 02, 2016: Asterias Biotherapeutics Announces Oral Presentation at ASGCT 19th Annual Meeting 94 Apr 20, 2016: Geron Announces Two Imetelstat Poster Presentations at the American Association for Cancer Research Annual Meeting 95 Mar 23, 2016: Argos Therapeutics Announces Initiation of a Phase 2 Clinical Trial of AGS-003 for the Treatment of Non-small Cell Lung Cancer in Combination with Standard-of-Care Chemotherapy 97 Mar 02, 2016: New trial launched to test cancer vaccine 97 Feb 24, 2016: Asterias Biotherapeutics Announces Successful End-of-Phase 2 Meeting with FDA for AST-VAC1 99 Jan 21, 2016: Asterias Biotherapeutics Announces Completion of Transfer of AST-VAC2 Manufacturing Process to Cancer Research UK as Milestone Towards Initiating Phase 1/2 Clinical Trial 100 Jan 14, 2016: Geron Announces Initiation of Janssen Phase 2/3 Clinical Trial of Imetelstat in Myelodysplastic Syndromes 101 Dec 10, 2015: Independent Data Monitoring Committee Recommends Continuation of ADAPT Phase 3 Clinical Trial of AGS-003 for Metastatic Renal Cell Carcinoma Following Second Planned Interim Analysis 102 Nov 05, 2015: Geron Announces Presentations at American Society of Hematology Annual Meeting 102 Nov 05, 2015: Janssen to Present Posters on Imetelstat at the 2015 American Society of Hematology Annual Meeting 103 Oct 30, 2015: Invectys starts the third dose level of its phase I clinical trial evaluating INVAC-1, an innovative anti-cancer therapeutic vaccine 104 Sep 16, 2015: Geron Announces Initiation of Janssen Phase 2 Clinical Trial of Imetelstat in Myelofibrosis 104 Appendix 106 Methodology 106 Coverage 106 Secondary Research 106 Primary Research 106 Expert Panel Validation 106 Contact Us 106 Disclaimer 107
List of Tables
Number of Products under Development for, H2 2016 10 Number of Products under Development by Therapy Area, H2 2016 11 Number of Products under Development by Indication, H2 2016 12 Comparative Analysis by Late Stage Development, H2 2016 14 Comparative Analysis by Early Stage Products, H2 2016 15 Comparative Analysis by Unknown Stage Development, H2 2016 16 Number of Products under Development by Companies, H2 2016 17 Products under Development by Companies, H2 2016 18 Products under Development by Companies, H2 2016 (Contd..1) 19 Products under Development by Companies, H2 2016 (Contd..2) 20 Number of Products under Investigation by Universities/Institutes, H2 2016 21 Products under Investigation by Universities/Institutes, H2 2016 22 Assessment by Monotherapy/Combination Products, H2 2016 23 Number of Products by Stage and Mechanism of Action, H2 2016 25 Number of Products by Stage and Route of Administration, H2 2016 27 Number of Products by Stage and Molecule Type, H2 2016 29 Pipeline by Adamis Pharmaceuticals Corporation, H2 2016 30 Pipeline by Argos Therapeutics, Inc., H2 2016 31 Pipeline by Asterias Biotherapeutics, Inc., H2 2016 32 Pipeline by e-Therapeutics Plc, H2 2016 33 Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 34 Pipeline by Inovio Pharmaceuticals, Inc., H2 2016 35 Pipeline by Invectys SA, H2 2016 36 Pipeline by Johnson & Johnson, H2 2016 37 Pipeline by Komipharm International Co., Ltd., H2 2016 38 Pipeline by Mediolanum farmaceutici S.p.A., H2 2016 39 Pipeline by Ultimovacs AS, H2 2016 40 Pipeline by Vaxon Biotech, H2 2016 41 Dormant Projects, H2 2016 85 Dormant Projects (Contd..1), H2 2016 86 Dormant Projects (Contd..2), H2 2016 87 Dormant Projects (Contd..3), H2 2016 88 Discontinued Products, H2 2016 89 Discontinued Products (Contd..1), H2 2016 90 Discontinued Products (Contd..2), H2 2016 91
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
